The newly approved indication allows two of Medtronic’s cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators to be used in patients with atrioventricular block and moderate, mild or severe heart failure, as well as providing pacing on both sides of the heart.
Clinical trials demonstrated a 27 percent reduction in death, heart failure-related urgent care visits and an increase in left ventricular end systolic volume index, a diagnostic measure of cardiac structure and function, according to an FDA news release.
More Articles on FDA Approvals:
FDA Approves Pradaxa for Deep Venous Thrombosis & Pulmonary Embolism
FDA Approves Alprolix for Hemophilia B Treatment
FDA Approves Otezla for Psoriatic Arthritis Treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.